Cat. No.:  DC5180   Featured
Chemical Structure
For research use only. We do not sell to patients.
We match the best price and quality on market.
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM.
Cas No.: 1194044-20-6
Chemical Name:
Synonyms: LY 2811376;LY-2811376
SMILES: C[C@]1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F
Formula: C15H14F2N4S
M.Wt: 320.36
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: LY2811376 is a BACE1 inhibitor with marked Ab-lowering effects in animal models. Oral administration of LY2811376 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99 and sAPPb. Brain Abeta levels were decreased 50% relative to vehicle-treated groups three hours after a 10 mg/kg dose of LY2811376. LY2811376 has pharmacologic properties sufficient to elicit robust BACE1 inhibition in vivo. The first orally available non-peptidic β-secretase inhibitor, LY2811376, was identified by fragment-based screening, lowered Aβ levels in a mouse model of Alzheimer's disease as well as in normal dogs. In healthy volunteers LY2811376 was safe and well tolerated and produced long-lasting reductions in Aβ levels. LY2811376 produced sustained and robust reductions in plasma and CSF Ab in subjects, confirming proof of mechanism. While the clinical development of LY2811376 is on hold, development of potent, clinically well-tolerated BACE1 inhibitors For the treatment of Alzheimer's disease appears plausible.For the detailed information of LY2811376, the solubility of LY2811376 in water, the solubility of LY2811376 in DMSO, the solubility of LY2811376 in PBS buffer, the animal experiment (test) of LY2811376, the cell expriment (test) of LY2811376, the in vivo, in vitro and clinical trial test of LY2811376, the EC50, IC50,and Affinity of LY2811376, Please contact DC Chemicals.
In Vivo:
In Vitro:
Kinase Assay:
Cell Assay:
Animal Administration:
Cat. No. Product name Field of application
DC9901 Verubecestat (MK-8931) MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase.
DC5053 LY2886721 LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.
DC5180 LY2811376 LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM.
DC8400 AZD3839 AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.